Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anticarcinogenic internal implant agent

A technology of implants and anti-cancer drugs, applied in the field of medicine, can solve problems such as treatment failure and enhancement

Inactive Publication Date: 2005-10-12
DASEN BIOLOGICAL PHARMA CO LTD
View PDF8 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The latter often leads to increased resistance of tumor cells to nitrosourea anticancer drugs, resulting in treatment failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0080] Put the weighed (80 mg) pharmaceutical excipient (polylactic acid (PLGA) with a molecular weight of 10,000) into a container, add a certain amount of organic solvent to dissolve and mix (subject to full dissolution), then add 10 mg of camox Ting and 10mg methoxy mustard, re-shake and vacuum dry to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anti-cancer in vivo implant containing 10% carmustine and 10% metoxymustine.

Embodiment 2

[0082] According to the above-mentioned process and the method described in Example 1, the anti-cancer in vivo implant is made, the difference is that the anti-cancer active ingredients contained are:

[0083] 1-50% of orestamustine, streptozocin, amustine, amustine, nimustine, bendamustine, dithiamustine, pofuramustine, carmomustine Mastine, emustine, ecomustine, dithiamustine, garmustine, formustine, estramustine, comustine, nemustine, mannustine, lomustine Lomustine, methyllomustine, semustine, ramustine, prednimustine, samustine, uramustine, taurmustine, tamustine, or siromustine Stine and 1-50% of methoxy mustard, mustard mustard, oxygen nitrogen mustard, glycyphosphoryl mustard, naphthalene mustard, nitrogen mustard hydrochloride, heteroaryl mustard, ortho mustard, card mustard, sulfur mustard mustard , triclosmustine, phosphamide mustard, ortho mustard, eucalyptus mustard, thymine mustard, uracil mustard, imidazole mustard, mannitol mustard, mannomustine, pentalensine ...

Embodiment 3

[0085] Put the weighed (80mg) pharmaceutical excipient (polylactic acid (PLGA) with a molecular weight of 25000) into the container, add a certain amount of organic solvent to dissolve and mix (subject to full dissolution), then add 10mg of nimustine and 10 mg of nocodazole, re-shake and dry in vacuo to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to obtain an anti-cancer in vivo implant containing 10% of nimustine and 10% of nocodazole.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An anticancer in vivo implant applied locally is prepared from the anticancer nitrosourea-type medicine, the anticancer synergist chosen from nitrogen mustard compound, mitotic inhibitor and antimetabolic anticancer medicine, and the biocompatible and biodegradable high-molecular polymer as medicinal additive.

Description

(1) Technical field [0001] The invention relates to an anticancer implant in vivo, belonging to the technical field of medicines. (2) Background technology [0002] The treatment of solid tumors mainly includes surgery, radiotherapy and chemotherapy. Among the various chemotherapeutic drugs used, nitrosourea anticancer drugs have obvious effects and have been widely used in various malignant tumors. However, further research found that the DNA repair function in many tumor cells increased significantly after the treatment. The latter often leads to enhanced resistance of tumor cells to nitrosourea anticancer drugs, resulting in treatment failure. [0003] Recently, a number of drugs have been found to increase the sensitivity of tumor cells to nitrosourea anticancer drugs, see Dolan et al. "Effects of O6-benzylguanine analogues on the cytotoxic sensitivity of human tumor cells to alkylating agents" Cancer Research 51, pp. 3367-3372 (1991) (Dolan et al., Cancer Res., 51, 3...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K31/17A61K45/06A61P35/00
Inventor 孔庆忠孙娟张红军宋邦强
Owner DASEN BIOLOGICAL PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com